Jefferies upgraded UCB to Buy from Hold with a price target of EUR 104, up from EUR 79. The firm’s latest doctor survey caused it to raise its Bimzelx peak sales estimate to over EUR 4B. Doctors are more positive on uptake post-approval viewing its clinical profile as superior to other IL-17s, suggesting less notable concern re suicidal ideation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UCBJF:
